This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|August 28, 2018
ABEC Expands Equipment Supply Capability
Author(s)BioPharm International Editors
The company is certified as a manufacturer of pressure vessels and components for use in China.
Advertisement
On Aug. 23, 2018, ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, announced that its manufacturing facility in Kells, County Meath, Ireland, has received certification from the People’s Republic of China as a qualified manufacturer of pressure vessels and components for use in China.
According to the company, the Kells site is the company’s second facility to obtain its China manufacture license (CML); its Springfield, MO facility obtained its CML in 2010. The Kells facility was granted a CML after an audit of its vessel engineering, manufacturing, and quality processes by the China Special Equipment Inspection & Research Institute.
The company reports that it has been investing in China for more than 10 years to support the expansion of China’s biotech industry, and pressure vessels are critical components of the systems used to manufacture biopharmaceuticals. The CML for Kells allows the company to provide fully-compliant systems from the United States and Europe, ensuring consistent and flexible supply in China, as well as supporting foreign companies who are establishing manufacturing facilities in China, as stated by ABEC.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5